Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT-210 in Active Ulcerative Colitis
NCT07692165Phase 2Recruiting
- Sponsor
- Innatus Therapeutics
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of INT-210 in ulcerative colitis (UC), sponsored by Innatus Therapeutics. Started Jun 2026; status: recruiting.
02
Drugs
INT-210
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07692165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692165.